Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study

Molecular Genetics and Metabolism

Volumn 110, Issue SUPPL., 2013, Pages

  Demirdas, Serwet ^a   Maurice Stam, Heleen ^a   Boelen, Carolien C A ^b   Hofstede, Floris C ^c   Janssen, Mirian C H ^d   Langendonk, Janneke G ^e   Mulder, Margot F ^f   Rubio Gozalbo, M Estela ^g   van Spronsen, Francjan J ^h   de Vries, Maaike ^d   Grootenhuis, Martha A ^a   Bosch, Annet M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Health related quality of life; HRQoL; Phenylketonuria; PKU; QoL; Quality of life

Indexed keywords

TETRAHYDROBIOPTERIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DIET; DISABKIDS CHRONIC GENERIC MODULE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTHER; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEWBORN SCREENING; PEDIATRIC QUALITY OF LIFE INVENTORY; PHENYLKETONURIA; PHYSICAL CAPACITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCHOOL CHILD; SOCIAL PSYCHOLOGY; TNO AZL ADULT QUALITY OF LIFE QUESTIONNAIRE;

ACADEMIC MEDICAL CENTER, AMSTERDAM; AMC; BH4; DISABKIDS; HEALTH RELATED QUALITY OF LIFE; HRQOL; PAH; PEDIATRIC QUALITY OF LIFE INVENTORY MEASUREMENT MODEL ™; PEDSQL; PHE; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIA; PKU; QOL; QUALITY OF LIFE; SD; STANDARD DEVIATION; TAAQOL; TETRAHYDROBIOPTERIN (BH4); THE DISABKIDS CHRONIC GENERIC MODULE; TNO-AZL ADULT QUALITY OF LIFE;

ADOLESCENT; ADULT; BIOPTERIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PHENYLKETONURIAS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889596324     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.09.015     Document Type: Article

References (36)

1. Scriver R., Levy H., Donlon J. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. The Online Metabolic and Molecular Bases of Inherited Diseases (OMMBID) 2008.
2. Verkerk P.H. 20-year national screening for phenylketonuria in The Netherlands. National Guidance Commission PKU. Ned. Tijdschr. Geneeskd. 1995, 139:2302-2305.
3. Blau N., van Spronsen F.J., Levy H.L. Phenylketonuria. Lancet 2010, 376:1417-1427.
4. van Spronsen F.J., Burgard P. The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J. Inherit. Metab. Dis. 2008, 31:673-679.
5. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria?. Lancet 2002, 360:55-57.
6. Belanger-Quintana A., Burlina A., Harding C.O., Muntau A.C. Up to date knowledge on different treatment strategies for phenylketonuria. Mol. Genet. Metab. 2011, 104:S19-S25. (Suppl.).
7. Feillet F., Agostoni C. Nutritional issues in treating phenylketonuria. J. Inherit. Metab. Dis. 2010, 33:659-664.
8. Levy H., Burton B., Cederbaum S., Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 2007, 92:287-291.
9. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
10. Blau N., Belanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F.J. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol. Genet. Metab. 2009, 96:158-163.
11. Anjema K., Venema G., Hofstede F.C., Carbasius Weber E.C., Bosch A.M., Ter Horst N.M., Hollak C.E., Jonkers C.F., Rubio-Gozalbo M.E., van der Ploeg E.M., et al. The 48-hour tetrahydrobiopterin loading test in patients with phenylketonuria: evaluation of protocol and influence of baseline phenylalanine concentration. Mol. Genet. Metab. 2011, 104:S60-S63. (Suppl.).
12. MacDonald A. Mac: Diet and compliance in phenylketonuria. Eur. J. Pediatr. 2000, 159:S136-S141.
13. MacDonald A., Gokmen-Ozel H., Van R.M., Burgard P. The reality of dietary compliance in the management of phenylketonuria. J. Inherit. Metab. Dis. 2010, 33:665-670.
14. Bosch A.M., Tybout W., van Spronsen F.J., de Valk H.W., Wijburg F.A., Grootenhuis M.A. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:29-34.
15. Landolt M.A., Nuoffer J.M., Steinmann B., Superti-Furga A. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J. Pediatr. 2002, 140:516-521.
16. Simon E., Schwarz M., Roos J., Dragano N., Geraedts M., Siegrist J., Kamp G., Wendel U. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual. Life Outcomes 2008, 6:25.
17. Thimm E., Schmidt L.E., Heldt K., Spiekerkoetter U. Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents. J. Inherit. Metab. Dis. 2013, 36:767-772.
18. Cotugno G., Nicolo R., Cappelletti S., Goffredo B.M., Dionisi V.C., Di C. V: Adherence to diet and quality of life in patients with phenylketonuria. Acta. Paediatr. 2011, 100:1144-1149.
19. Varni J.W., Limbers C.A. The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents. Pediatr. Clin. North Am. 2009, 56:843-863.
20. Engelen V., Haentjens M.M., Detmar S.B., Koopman H.M., Grootenhuis M.A. Health related quality of life of Dutch children: psychometric properties of the PedsQL in the Netherlands. BMC Pediatr. 2009, 9:68.
21. Fekkes M., Kamphuis R.P., Ottenkamp P.J. Health-related quality of life in young adults with minor congenital heart disease. Psychol. Health 2001, 16:239-250.
22. Bullinger M., Schmidt S., Petersen C. Assessing quality of life of children with chronic health conditions and disabilities: a European approach. Int. J. Rehabil. Res. 2002, 25:197-206.
23. Ravens-Sieberer U., Schmidt S., Gosch A., Erhart M., Petersen C., Bullinger M. Measuring subjective health in children and adolescents: results of the European KIDSCREEN/DISABKIDS Project. Psychosoc. Med. 2007, 4:Doc08.
24. Gentile J.K., ten Hoedt A.E., Bosch A.M. Psychosocial aspects of PKU: hidden disabilities - a review. Mol. Genet. Metab. 2010, 99(Suppl. 1):S64-S67.
25. Sprangers M.A., Schwartz C.E. Integrating response shift into health-related quality of life research: a theoretical model. Soc. Sci. Med. 1999, 48:1507-1515.
26. Burgard P., Schmidt E., Rupp A., Schneider W., Bremer H.J. Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur. J. Pediatr. 1996, 155(Suppl. 1):S33-S38.
27. Griffiths P.V., Demellweek C., Fay N., Robinson P.H., Davidson D.C. Wechsler subscale IQ and subtest profile in early treated phenylketonuria. Arch. Dis. Child. 2000, 82:209-215.
28. Brumm V.L., Grant M.L. The role of intelligence in phenylketonuria: a review of research and management. Mol. Genet. Metab. 2010, 99(Suppl. 1):S18-S21.
29. Fonnesbeck C.J., McPheeters M.L., Krishnaswami S., Lindegren M.L., Reimschisel T. Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis. J. Inherit. Metab. Dis. 2013, 36:757-766.
30. Campistol J., Gassio R., Artuch R., Vilaseca M.A. Neurocognitive function in mild hyperphenylalaninemia. Dev. Med. Child Neurol. 2011, 53:405-408.
31. Anastasoaie V., Kurzius L., Forbes P., Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol. Genet. Metab. 2008, 95:17-20.
32. Christ S.E., Huijbregts S.C., de Sonneville L.M., White D.A. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol. Genet. Metab. 2010, 99(Suppl. 1):S22-S32.
33. ten Hoedt A.E., Maurice-Stam H., Boelen C.C., Rubio-Gozalbo M.E., van Spronsen F.J., Wijburg F.A., Bosch A.M., Grootenhuis M.A. Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life. J. Inherit. Metab. Dis. 2011, 34:391-398.
34. Janzen D., Nguyen M. Beyond executive function: non-executive cognitive abilities in individuals with PKU. Mol. Genet. Metab. 2010, 99(Suppl. 1):S47-S51.
35. Ziesch B., Weigel J., Thiele A., Mutze U., Rohde C., Ceglarek U., Thiery J., Kiess W., Beblo S. Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life. J. Inherit. Metab. Dis. 2012, 35:983-992.
36. Ten Hoedt A.E., de Sonneville L.M., Francois B., Ter Horst N.M., Janssen M.C., Rubio-Gozalbo M.E., Wijburg F.A., Hollak C.E., Bosch A.M. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J. Inherit. Metab. Dis. 2011, 34:165-171.